StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a report published on Saturday. The brokerage issued a sell rating on the stock.
Bio-Path Stock Performance
Shares of BPTH opened at $0.75 on Friday. The business has a fifty day moving average of $0.98 and a 200 day moving average of $1.56. Bio-Path has a 52-week low of $0.61 and a 52-week high of $12.37.
Hedge Funds Weigh In On Bio-Path
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path at the end of the most recent reporting period. 5.74% of the stock is currently owned by institutional investors.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Articles
- Five stocks we like better than Bio-Path
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Overbought Stocks Explained: Should You Trade Them?
- Applied Materials Market Capitulates: Now is the Time to Buy
- Best Stocks Under $5.00
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
